Title: Full Text of HB2346
Official Title: 
Number of Sections: 1
Source: versions - House Amendment 001
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly Rep. Laura Faver DiasFiled: 4/8/2025   10400HB2346ham001LRB104 06540 BDA 24827 a1AMENDMENT TO HOUSE BILL 2346 2    AMENDMENT NO. ______. Amend House Bill 2346 by replacing 3everything after the enacting clause with the following: 4    "Section 5. The Illinois Drug Reuse Opportunity Program 5Act is amended by changing Sections 5, 45, and 55 and by adding 6Section 70 as follows: 7    (410 ILCS 715/5)8    Sec. 5. Definitions. In this Act:9    "Controlled substance" means a drug, substance, or 10immediate precursor in Schedules I through V of 21 CFR 1308.11    "Department" means the Illinois Department of Public 12Health. 13    "Dispense" has the same meaning as defined in Section 3 of 14the Pharmacy Practice Act.15    "Donor" means any person, including an individual member 16of the public, or any entity legally authorized to possess   10400HB2346ham001- 2 -LRB104 06540 BDA 24827 a1medicine, including, but not limited to, a wholesaler or 2distributor, third party logistic provider, pharmacy, 3dispenser, clinic, surgical or health center, detention and 4rehabilitation center, jail, prison laboratory, medical or 5pharmacy school, prescriber or other health care professional, 6long-term care facility, or healthcare facility. "Donor" 7includes government agencies and entities that are federally 8authorized to possess medicine, including, but not limited to, 9drug manufacturers, repackagers, relabelers, outsourcing 10facilities, health care facilities operated by the U.S. 11Department of Veterans Affairs, and prisons.12    "Drug" means a prescription drug, over-the-counter drug, 13or supplies needed to administer a prescription or 14over-the-counter drug.15    "Eligible patient" means an individual:16        (1) with a prescription for the drug, if a 17    prescription is required to dispense the drug, or who 18    reports symptoms treated by the drug if the drug is 19    over-the-counter; and20        (2) who is registered with the drug's manufacturer in 21    accordance with federal Food and Drug Administration 22    requirements, if the registration is required to dispense 23    the drug.24    "Manufacturer" has the same meaning as defined in Section 2515 of the Wholesale Drug Distribution Licensing Act.26    "Pharmacist" means an individual licensed to engage in the   10400HB2346ham001- 3 -LRB104 06540 BDA 24827 a1practice of pharmacy under the Pharmacy Practice Act or 2licensed to engage in the practice of pharmacy in another 3state.4    "Practitioner" means a person licensed in this State to 5dispense or administer drugs or who is licensed in another 6state as a person authorized to dispense or administer drugs.7    "Prescription drug" means any prescribed drug that may be 8legally dispensed by a pharmacy. "Prescription drug" does not 9include a drug for the treatment of cancer that can only be 10dispensed to a patient registered with the drug manufacturer 11in accordance with the federal Food and Drug Administration's 12requirements.13    "Priority patient" means an eligible patient who is an 14Illinois resident and who is indigent, uninsured, 15underinsured, or enrolled in a public health benefits program.16    "Recipient" means any person or entity legally authorized 17to possess medicine with a license or permit in the state in 18which the person or entity is located, including, but not 19limited to, a wholesaler or distributor, reverse distributor, 20repackager, hospital, pharmacy, or clinic.21    "Returns processor" has the same meaning as defined in 22paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 23includes, but is not limited to, a reverse distributor.24    "Unopened tamper-evident packaging" has the same meaning 25as defined in the United States Pharmacopeia (USP) General 26Chapter 659, Packaging and Storage Requirements, including,   10400HB2346ham001- 4 -LRB104 06540 BDA 24827 a1but not limited to, unopened unit-dose, multiple-dose, 2immediate, secondary, and tertiary packaging.3(Source: P.A. 102-389, eff. 1-1-22.) 4    (410 ILCS 715/45)5    Sec. 45. Recordkeeping requirements. When performing any 6action associated with a program under this Act or otherwise 7processing a donated drug for tax, manufacturer, or other 8credit, a recipient shall be considered to be acting as a 9returns processor and shall comply with all recordkeeping 10requirements for nonsalable nonsaleable returns under federal 11law. Records maintained under this Act may be accessed by the 12Department upon request. 13(Source: P.A. 102-389, eff. 1-1-22.) 14    (410 ILCS 715/55)15    Sec. 55. Retention of records. All records required under 16this Act shall be retained in physical or electronic format 17and on or off the recipient's premises for a period of 6 years. 18Donors or recipients may contract with one another or a third 19party to create or maintain records on each other's behalf. An 20identifier, such as a serial number or bar code, may be used in 21place of any or all information required by a record or label 22pursuant to this Act if it allows for such information to be 23readily retrievable. Upon request by a State or federal 24regulatory agency, the identifier used for requested records   10400HB2346ham001- 5 -LRB104 06540 BDA 24827 a1shall be replaced with the original information. An identifier 2shall not be used on patient labels when dispensing or 3administering a drug. Records maintained under this Act may be 4accessed by the Department upon request. 5(Source: P.A. 102-389, eff. 1-1-22.) 6    (410 ILCS 715/70 new)7    Sec. 70. Program support provided by the Department.8    (a) The Department shall:9        (1) develop, maintain, and publish on its website 10    information regarding the names and locations of 11    pharmacies participating in the Illinois Drug Reuse 12    Opportunity Program;13        (2) educate pharmacies in the State about the Illinois 14    Drug Reuse Opportunity Program and how to participate in 15    it voluntarily;16        (3) develop and publish educational materials to allow 17    program participants and the Department to inform the 18    general public about the purposes and benefits of the 19    program; and20        (4) collect information from participants and publish 21    the information in an annual report to the General 22    Assembly by December 31 of each calendar year, beginning 23    December 31, 2026.24    (b) Pharmacy participants are required to notify the 25Department of their participation in any program under this   10400HB2346ham001- 6 -LRB104 06540 BDA 24827 a1Act and report any data required in a format established by the 2Department.".


================================================================================

Raw Text:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly Rep. Laura Faver DiasFiled: 4/8/2025   10400HB2346ham001LRB104 06540 BDA 24827 a1AMENDMENT TO HOUSE BILL 2346 2    AMENDMENT NO. ______. Amend House Bill 2346 by replacing 3everything after the enacting clause with the following: 4    "Section 5. The Illinois Drug Reuse Opportunity Program 5Act is amended by changing Sections 5, 45, and 55 and by adding 6Section 70 as follows: 7    (410 ILCS 715/5)8    Sec. 5. Definitions. In this Act:9    "Controlled substance" means a drug, substance, or 10immediate precursor in Schedules I through V of 21 CFR 1308.11    "Department" means the Illinois Department of Public 12Health. 13    "Dispense" has the same meaning as defined in Section 3 of 14the Pharmacy Practice Act.15    "Donor" means any person, including an individual member 16of the public, or any entity legally authorized to possess   10400HB2346ham001- 2 -LRB104 06540 BDA 24827 a1medicine, including, but not limited to, a wholesaler or 2distributor, third party logistic provider, pharmacy, 3dispenser, clinic, surgical or health center, detention and 4rehabilitation center, jail, prison laboratory, medical or 5pharmacy school, prescriber or other health care professional, 6long-term care facility, or healthcare facility. "Donor" 7includes government agencies and entities that are federally 8authorized to possess medicine, including, but not limited to, 9drug manufacturers, repackagers, relabelers, outsourcing 10facilities, health care facilities operated by the U.S. 11Department of Veterans Affairs, and prisons.12    "Drug" means a prescription drug, over-the-counter drug, 13or supplies needed to administer a prescription or 14over-the-counter drug.15    "Eligible patient" means an individual:16        (1) with a prescription for the drug, if a 17    prescription is required to dispense the drug, or who 18    reports symptoms treated by the drug if the drug is 19    over-the-counter; and20        (2) who is registered with the drug's manufacturer in 21    accordance with federal Food and Drug Administration 22    requirements, if the registration is required to dispense 23    the drug.24    "Manufacturer" has the same meaning as defined in Section 2515 of the Wholesale Drug Distribution Licensing Act.26    "Pharmacist" means an individual licensed to engage in the   10400HB2346ham001- 3 -LRB104 06540 BDA 24827 a1practice of pharmacy under the Pharmacy Practice Act or 2licensed to engage in the practice of pharmacy in another 3state.4    "Practitioner" means a person licensed in this State to 5dispense or administer drugs or who is licensed in another 6state as a person authorized to dispense or administer drugs.7    "Prescription drug" means any prescribed drug that may be 8legally dispensed by a pharmacy. "Prescription drug" does not 9include a drug for the treatment of cancer that can only be 10dispensed to a patient registered with the drug manufacturer 11in accordance with the federal Food and Drug Administration's 12requirements.13    "Priority patient" means an eligible patient who is an 14Illinois resident and who is indigent, uninsured, 15underinsured, or enrolled in a public health benefits program.16    "Recipient" means any person or entity legally authorized 17to possess medicine with a license or permit in the state in 18which the person or entity is located, including, but not 19limited to, a wholesaler or distributor, reverse distributor, 20repackager, hospital, pharmacy, or clinic.21    "Returns processor" has the same meaning as defined in 22paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 23includes, but is not limited to, a reverse distributor.24    "Unopened tamper-evident packaging" has the same meaning 25as defined in the United States Pharmacopeia (USP) General 26Chapter 659, Packaging and Storage Requirements, including,   10400HB2346ham001- 4 -LRB104 06540 BDA 24827 a1but not limited to, unopened unit-dose, multiple-dose, 2immediate, secondary, and tertiary packaging.3(Source: P.A. 102-389, eff. 1-1-22.) 4    (410 ILCS 715/45)5    Sec. 45. Recordkeeping requirements. When performing any 6action associated with a program under this Act or otherwise 7processing a donated drug for tax, manufacturer, or other 8credit, a recipient shall be considered to be acting as a 9returns processor and shall comply with all recordkeeping 10requirements for nonsalable nonsaleable returns under federal 11law. Records maintained under this Act may be accessed by the 12Department upon request. 13(Source: P.A. 102-389, eff. 1-1-22.) 14    (410 ILCS 715/55)15    Sec. 55. Retention of records. All records required under 16this Act shall be retained in physical or electronic format 17and on or off the recipient's premises for a period of 6 years. 18Donors or recipients may contract with one another or a third 19party to create or maintain records on each other's behalf. An 20identifier, such as a serial number or bar code, may be used in 21place of any or all information required by a record or label 22pursuant to this Act if it allows for such information to be 23readily retrievable. Upon request by a State or federal 24regulatory agency, the identifier used for requested records   10400HB2346ham001- 5 -LRB104 06540 BDA 24827 a1shall be replaced with the original information. An identifier 2shall not be used on patient labels when dispensing or 3administering a drug. Records maintained under this Act may be 4accessed by the Department upon request. 5(Source: P.A. 102-389, eff. 1-1-22.) 6    (410 ILCS 715/70 new)7    Sec. 70. Program support provided by the Department.8    (a) The Department shall:9        (1) develop, maintain, and publish on its website 10    information regarding the names and locations of 11    pharmacies participating in the Illinois Drug Reuse 12    Opportunity Program;13        (2) educate pharmacies in the State about the Illinois 14    Drug Reuse Opportunity Program and how to participate in 15    it voluntarily;16        (3) develop and publish educational materials to allow 17    program participants and the Department to inform the 18    general public about the purposes and benefits of the 19    program; and20        (4) collect information from participants and publish 21    the information in an annual report to the General 22    Assembly by December 31 of each calendar year, beginning 23    December 31, 2026.24    (b) Pharmacy participants are required to notify the 25Department of their participation in any program under this   10400HB2346ham001- 6 -LRB104 06540 BDA 24827 a1Act and report any data required in a format established by the 2Department.".